Capital Counsel’s Eli Lilly LLY Stock Holding History

Capital Counsel’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-462	Closed	-$382K	–	59
2025 Q1	$382K	Buy	462 +170	+58%	+$141K	0.02%	42
2024 Q4	$225K	Hold	292	–	–	0.01%	49
2024 Q3	$259K	Buy	292 +7	+2%	+$6.29K	0.01%	48
2024 Q2	$258K	Hold	285	–	–	0.01%	46
2024 Q1	$222K	Buy	+285	New	+$203K	0.01%	52
2016 Q1	–	Sell	-8,080	Closed	-$681K	–	98
2015 Q4	$681K	Buy	8,080 +4,600	+132%	+$382K	0.04%	67
2015 Q3	$291K	Hold	3,480	–	–	0.02%	98
2015 Q2	$291K	Hold	3,480	–	–	0.01%	115
2015 Q1	$253K	Hold	3,480	–	–	0.01%	123
2014 Q4	$240K	Hold	3,480	–	–	0.01%	122
2014 Q3	$226K	Hold	3,480	–	–	0.01%	123
2014 Q2	$216K	Sell	3,480 -100	-3%	-$5.97K	0.01%	129
2014 Q1	$211K	Buy	+3,580	New	+$200K	0.01%	132

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Counsel's LLY Position: Q2 2025 in Review

Capital Counsel sold out of Eli Lilly (LLY) in Q2 2025, closing a stake of 462 shares — an estimated $382K sold.

Capital Counsel first reported a position in LLY in Q1 2014 and held it in 13 quarters. The position peaked at $681K in Q4 2015. 3,906 funds tracked by Wall St. Rank hold LLY as of Q2 2025.

Capital Counsel reported no remaining Eli Lilly position as of Q2 2025 after selling out during the quarter.
Capital Counsel sold 462 Eli Lilly shares in Q2 2025, an estimated $382K.
Capital Counsel first reported a position in Eli Lilly in Q1 2014 and held it in 13 quarters.
Capital Counsel's Eli Lilly position peaked at $681K in Q4 2015.
3,906 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2025.

Based on Capital Counsel's 13F filing for Q2 2025, filed 13 Aug 2025.